360° SearchNetwork Hot Spots Trends Time Series

Pixuvri

Type: Product

Name: Pixuvri

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Cell Therapeutics, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 02:30 PM

Unknown AnalystSo I'm [indiscernible]. I cover biotech space in Europe for UBS. I just would like to introduce Dr. Blanco, CEO for CTI. So you can have probably a 25 minutes presentation.James A. BiancoThank you. Good afternoon. As is typical of the presentations ... [Published Seeking Alpha - May 22 2013]

Entities: Patient, Ruxolitinib, SPLEEN, thrombocyte, Pixuvri

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Cell Therapeutics receives German Federal Joint Committee's final benefit assessment report for Pixuvri

Cell Therapeutics, Inc. (CTI), a biopharmaceutical company, announced that Germany's Federal Joint Committee (G-BA) has issued its final benefit assessment report for Pixuvri (pixantrone), which is indicated as a monotherapy for the treatment of adult ... [Published PharmaBiz - May 21 2013]

Entities: Pixuvri, Cell Therapeutics Inc, Phase III, Patient, Federal

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Germany’s G-BA Finds No Added Benefit For CTI’s Pixuvri, Exposing Price

Germany’s G-BA lets through Cell Therapeutics’ Pixuvri for aggressive B-cell non-Hodgkin's lymphoma but finds no added benefit over existing therapies, meaning its price could come under pressure. ... [Published The Rose Sheet - May 20 2013]

Entities: Pixuvri, Germany, Cell Therapeutics Inc

First reported May 20 2013 - Updated May 20 2013 - 1 reports

German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone)

CELL THERAPEUTICS INC Symbol U : CTIC Recent Sedar Documents German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone) ... [Published Stockwatch - May 20 2013]

Entities: pixantrone, Pixuvri, Federal

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Cell Therapeutics reports higher Q1 net loss, provides outlook for 2013

Cell Therapeutics, Inc., a biopharmaceutical company, has reported that net loss for the first quarter ended March 31, 2013 was $19.38 million, or $0.18 loss per share, compared to a net loss of $17.45 million, or $0.43 loss per share, for the same quarter ... [Published Individual.com - May 16 2013]

Entities: Cell Therapeutics Inc, Pixuvri, James Bianco, myelofibrosis, Non-Hodgkin's Lymphoma

First reported May 04 2013 - Updated May 04 2013 - 1 reports

Cell Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript

4:30 PM ETOperatorGood day, ladies and gentlemen. Thank you for standing by. Welcome to the Cell Therapeutics Q1 2013 Financial Results Conference Call. [Operator Instructions] This conference is being recorded today, May 2, 2013. I would now like to ... [Published Seeking Alpha - May 04 2013]

Entities: Pixuvri, myelofibrosis, thrombocyte, Patient

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Cell Therapeutics' loss widens as it begins selling cancer drug

Cell Therapeutics Inc. generated $1.1 million revenues through European sales of its cancer drug Pixuvri, but still posted a $19.4 million loss for the first quarter of 2013.That’s more than the $17.4 million loss for the first quarter of 2012.As of March ... [Published Puget Sound Business Journal - May 02 2013]

Entities: Cell Therapeutics Inc, antineoplastic, Pixuvri

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Cell Therapeutics Reports First Quarter 2013 Financial Results

SOURCE Cell Therapeutics, Inc.- Conference call scheduled today at 4:30 p.m. Eastern time -SEATTLE"In the first quarter, we generated initial commercial sales of PIXUVRI® in countries in the European Union where there is market access pending the completion ... [Published KWQC - May 02 2013]

Entities: Pixuvri, Cell Therapeutics Inc, Non-Hodgkin's Lymphoma, European Union, James Bianco

First reported Apr 24 2013 - Updated Apr 24 2013 - 1 reports

Human medicines European Public Assessment Report (EPAR): Pixuvri, pixantrone dimaleate, Revision: 2, Authorised

[Published Pending EC decisions and European Public Assess ... - Apr 24 2013]

Entities: pixantrone, Pixuvri

First reported Apr 16 2013 - Updated Apr 16 2013 - 1 reports

NICE raises ‘uncertainties’ over Pixuvri

Cell Therapeutics’ Pixuvri (pixantrone) has not been recommended by NICE in draft guidance as a treatment option for an aggressive form of non-Hodgkin’s lymphoma. ... [Published Pharma Field - Apr 16 2013]

Entities: Pixuvri, pixantrone, Cell Therapeutics Inc

First reported Apr 11 2013 - Updated Apr 11 2013 - 1 reports

NICE seeks views on draft guidance for non-Hodgkin's lymphoma treatment

A treatment for a type of non-Hodgkin's lymphoma is not recommended for NHS use in draft NICE guidance. An independent committee concluded there was insufficient evidence to show that pixantrone (Pixuvri, Cell Therapeutics) is more effective than current ... [Published NICE | National Institute for Health and Clinic ... - Apr 11 2013]

Entities: pixantrone, NHS, Pixuvri, Cell Therapeutics Inc

First reported Dec 18 2012 - Updated Dec 18 2012 - 1 reports

CTI announces preclinical study of Pixuvri, provides mechanism for lower cardiotoxicity in patients with multiply relapse

Biopharmaceutical company Cell Therapeutics, Inc. (CTI) has announced that results from a preclinical study of Pixuvri (pixantrone) providing potential mechanisms for lower cardiotoxicity in patients treated with Pixuvri who received prior doxorubicin ... [Published PharmaBiz - Dec 18 2012]

Entities: Pixuvri, doxorubicin, National Hockey League, anthracycline

Quotes

...standard of care for this stage of the disease, prior to the approval of Pixuvri in the EU," said James A Bianco, MD, president and CEO of CTI. "Pixuvri is the first medicinal product approved in the EU for the treatment of patients with aggressive non-Hodgkin B-cell lymphomas who have failed two or three prior lines of therapy, which was based on results from the only phase III study conducted in this patient population. We appreciate the Joint Committee recognizing this conundrum and providing CTI the opportunity to work with payors to arrive at an equitable price for Pixuvri, based on the cost associated with unlicensed agents or regimens currently being utilized by physicians in Germany."

Cell Therapeutics receives German Federal Joint Committee's final benefit assessment report for P ... [Published PharmaBiz - May 21 2013]

...Union where there is market access pending the completion of the reimbursement process," said James Bianco, M D , President and CEO of CTI. "Although it is early in the launch, we are pleased with the interest and receptivity of PIXUVRI by key lymphoma opinion leaders who treat patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) and who recognize the significant unmet need that exists for these patients. In addition, our Phase III PERSIST-1 clinical trial of pacritinib, an oral, once-daily JAK2/FLT3 inhibitor, in myelofibrosis continues to progress with the opening of additional sites and growing enrollment."

Cell Therapeutics reports higher Q1 net loss, provides outlook for 2013 [Published Individual.com - May 16 2013]

"During the fourth quarter 2012, we began making PIXUVRI available to healthcare providers in..."

Cell Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results [Published Financial Services - Feb 28 2013]

"Regulators want a lot of pen strokes up and down that provide a much more unique-looking name. It is more readable or interpretable if it has a lot of (Zs and Xs)" said Brannon Cashion, Addison Whitney's president

Time to Refill Your Prescription For Zxygjfb [Published In the Pipeline - Jan 28 2013]

More Content

sort by: Date \| Relevance
Cell Therapeutics, Inc. Presents at UBS Global ... [Published Seeking Alpha - May 22 2013]
Cell Therapeutics receives German Federal Joint... [Published PharmaBiz - May 21 2013]
Gemeinsamer Bundesausschuss (G-BA) gibt Beschlu... [Published PR Newswire: Health - May 21 2013]
Germany’s G-BA Finds No Added Benefit For CTI’s... [Published The Rose Sheet - May 20 2013]
German Federal Joint Committee (G-BA) Issues Fi... [Published Stockwatch - May 20 2013]
German Federal Joint Committee (G-BA) Issues Fi... [Published PR Newswire: General Business - May 20 2013]
Cell Therapeutics reports higher Q1 net loss, p... [Published Individual.com - May 16 2013]
Cell Therapeutics Management Discusses Q1 2013 ... [Published Seeking Alpha - May 04 2013]
Cell Therapeutics' loss widens as it begins sel... [Published Puget Sound Business Journal - May 02 2013]
Cell Therapeutics Reports First Quarter 2013 Fi... [Published KWQC - May 02 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Apr 24 2013]
Cell Therapeutics, Inc. (CTIC) - Financial and ... [Published TransWorldNews - Apr 21 2013]
NICE raises ‘uncertainties’ over Pixuvri [Published Pharma Field - Apr 16 2013]
NICE seeks views on draft guidance for non-Hodg... [Published NICE \| National Institute for Health and Clinic ... - Apr 11 2013]
Draft NICE Guidance for Aggressive non-Hodgkin ... [Published PR Newswire: General Business - Apr 11 2013]
Uneasy Lies The Head That Wears a Financings of... [Published The IN VIVO Blog - Apr 05 2013]
4 Healthcare Stock Stories for the End Of The T... [Published Wall St. Cheat Sheet - Mar 28 2013]
German Institute for Quality and Efficiency in ... [Published PR Newswire: Health - Mar 02 2013]
IQWiG veröffentlicht Dossierbewertung im Rahmen... [Published PR Newswire: Health - Mar 02 2013]
German Institute for Quality and Efficiency in ... [Published PR Newswire: Health - Mar 02 2013]
Cell Therapeutics Reports Fourth Quarter and Fu... [Published Financial Services - Feb 28 2013]
Time to Refill Your Prescription For Zxygjfb [Published In the Pipeline - Jan 28 2013]
2 Highly Speculative Biotech Stocks Worth A Loo... [Published Healthcare Sector and Stocks Analysis from Seek ... - Dec 18 2012]
CTI announces preclinical study of Pixuvri, pro... [Published PharmaBiz - Dec 18 2012]
Preclinical Study Provides Potential Mechanisms... [Published PR Newswire: General Business - Dec 17 2012]
PennyStock101.com Reports 3 Penny Stocks with M... [Published PRWeb - Sep 07 2012]

Blogs

sort by: Date \| Relevance
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Apr 24 2013]
NICE seeks views on draft guidance for non-Hodg... [Published NICE \| National Institute for Health and Clinic ... - Apr 11 2013] A treatment for a type of non-Hodgkin's lymphoma is not recommended for NHS use in draft NICE guidance. An independent committee concluded there was insufficient evidence to show that pixantrone (Pixuvri, Cell Therapeutics) is more effective than current ...
Uneasy Lies The Head That Wears a Financings of... [Published The IN VIVO Blog - Apr 05 2013] Compared to other types of financing, royalty-based deals in the biopharma world are rare. That’s because a company needs products with future revenue to parlay into a near-term lump sum, and the relative few companies that have such products often ...
4 Healthcare Stock Stories for the End Of The T... [Published Wall St. Cheat Sheet - Mar 28 2013] Gilead Sciences ( NASDAQ:GILD ): Closing price $48.94 Gilead has provided an update on ION-1, its Phase 3 clinical trial examining a once-daily fixed-dose combination of the nucleotide sofosbuvir and the NS5A inhibitor ledipasvir with and without ...
Time to Refill Your Prescription For Zxygjfb [Published In the Pipeline - Jan 28 2013] The brand names of drugs are famously odd. But they seem to be getting odder. That's the conclusion of a longtime reader, who sent this along: I was recently perusing through the recent drug approval list and was struck by how strange the trade names ...

Press Releases

sort by: Date \| Relevance
Gemeinsamer Bundesausschuss (G-BA) gibt Beschlu... [Published PR Newswire: Health - May 21 2013]
German Federal Joint Committee (G-BA) Issues Fi... [Published PR Newswire: General Business - May 20 2013]
Draft NICE Guidance for Aggressive non-Hodgkin ... [Published PR Newswire: General Business - Apr 11 2013]
German Institute for Quality and Efficiency in ... [Published PR Newswire: Health - Mar 02 2013]
IQWiG veröffentlicht Dossierbewertung im Rahmen... [Published PR Newswire: Health - Mar 02 2013]